BioArctic’s Partner Eisai Raises Forecast for Alzheimer’s Drug
When Eisai presented Leqembi sales simulations at its May 2026 IR Day, BioArctic (NASDAQ: BRC) faces critical shareholder scrutiny over its royalty exposure and market share positioning. Eisai’s ¥300B 2028 ... Read More